AOD-9604 research guide

AOD-9604 in Chokhatauri — Fat Loss Peptide Research Guide

AOD-9604 research guide for Chokhatauri. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.

Skip to Sourcing Guide Order AOD-9604 →

Finding AOD-9604 in Chokhatauri

Unlike general health products stocked in every health store, AOD-9604 reaches researchers through a specialist research supply market that Chokhatauri residents access almost entirely online. The upside of this online-only market is that serious vendors compete aggressively on their analytical documentation, giving researchers access to better quality signals than any physical store could provide. Separating quality AOD-9604 from the rest of the market comes down to three things: an HPLC chromatogram showing ≥98% purity, mass spec data confirming the correct molecular weight, and a batch-specific endotoxin panel. The sections below cover what Chokhatauri researchers need to know about purchasing, testing, and working with AOD-9604 for legitimate research applications.

What Studies Say About AOD-9604

The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Chokhatauri researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.

AOD-9604 Purchasing Guide

The most effective path to quality AOD-9604 is starting with community forums — peptide forums maintain informal vendor reputation databases that are more reliable than search results. Mass spectrometry in the COA confirms that the main HPLC peak is actually AOD-9604 and not a different peptide of similar polarity — HPLC purity alone does not confirm what the compound actually is. For Chokhatauri researchers evaluating new suppliers: a modest first purchase to test the product before placing larger orders is what experienced peptide researchers consistently do. Store lyophilised AOD-9604 at −20°C until ready to use; reconstitute only the quantity required for your immediate research and keep the remainder frozen.

Order AOD-9604 — ships to Chokhatauri
COA-verified · International tracking · Research grade
Order Now →

AOD-9604 Safety, Handling & Research Protocols

Research compound status for AOD-9604 means risk characterisation relies on animal studies, in-vitro work, and limited human observations — rather than the comprehensive clinical trial data that characterises approved medications. Proper handling of AOD-9604 requires strict sterile technique during reconstitution — prep pad-cleaned septum, single-use needles, uncontaminated workspace — and temperature control throughout the entire workflow. Bacterial endotoxin contamination is the greatest safety hazard associated with research-grade peptides — verify endotoxin testing is included in the batch-specific COA before any injectable research application. The research literature on AOD-9604 should be reviewed carefully before beginning any research — study approaches, dose levels, and measured endpoints vary significantly and results do not always generalise across models.

Frequently Asked Questions

How does AOD-9604 differ from growth hormone?

AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.

What is the clinical trial history of AOD-9604?

AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.

What is AOD-9604?

AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.

Order AOD-9604 today
COA-verified · International shipping available
Order Now →